Clinical Trial Update: Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing different doses of BI 1467335 to placebo in patients with non-alcoholic fatty liver disease (NAFLD) has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• BI 1467335 (BI 1467335)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-06-11